Publication | Open Access
Cost-Effectiveness Analysis of Allopurinol Versus Febuxostat in Chronic Gout Patients: A U.S. Payer Perspective
29
Citations
21
References
2015
Year
Febuxostat was found to be a cost-effective option compared with allopurinol based on a U.S. payer perspective.
| Year | Citations | |
|---|---|---|
Page 1
Page 1